The European Medicines Agency is planning to freeze the UK out of its drug safety monitoring system after Brexit – despite the UK government's aim to maintain a close workin
The UK could find its ability to counter the threat of a ‘super-gonorrhoea’ and other infectious diseases hampered if the country loses access to the EU’s early warning health system, the B
Europe’s medicines regulator is expecting higher-than-anticipated staff departures as a result of its Brexit-induced move from London to Amsterdam next year.
With the pharma industry putting the ‘blockbuster’ age behind it and moving into meeting needs across myriad niche disease areas, what is the impact and therefore change of requirement in terms of
Britain’s pharma trade body has issued a fresh Brexit warning, saying it would be disadvantageous to both the UK and the EU if drugs regulation diverges as a result of the political changes
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.